Clinical Trial

A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity following multiple intravenous (IV) ascending doses of ABBV-8736 in healthy adult participants.
Protocol Amendment History 1 change
critical Trial completed 2026-04-29
Trial Details
NCT Number NCT07141199
Lead Sponsor AbbVie
Conditions Healthy Volunteer
Enrollment 24 participants
Start Date 2025-09-02
Primary Completion 2026-03-23 (estimated)
Study Completion 2026-03-23 (estimated)
Updated on ClinicalTrials.gov 2026-04-28